Zongertinib (Hernexeos) 60mg | China-Sourced HER2 Inhibitor for NSCLC | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Hernexeos (Zongertinib) — China-Mainland Version

Hernexeos is the brand name of zongertinib, a first-in-class oral HER2 tyrosine kinase inhibitor developed by Boehringer Ingelheim. In China, this medicine is marketed under the Chinese brand name 圣赫途 (Shèng Hè Tú) and is supplied as the China-Mainland version in a convenient 60 mg × 60 tablets bottle. The China-Mainland edition carries the full marketing authorization from the National Medical Products Administration (NMPA) and is the same originator molecule sold by Boehringer Ingelheim worldwide.

Zongertinib was designed specifically for adults whose non-squamous non-small cell lung cancer (NSCLC) carries a HER2 (ERBB2) tyrosine kinase domain activating mutation — a molecular subtype that has historically had few targeted treatment options. For patients in China and neighbouring regions who need this drug on an ongoing basis, the China-Mainland originator version represents the most direct access to the originator molecule at a price point that is meaningfully lower than many Western list prices.

What Is Hernexeos (Zongertinib)?

Hernexeos is an oral tablet formulation of zongertinib, a small-molecule kinase inhibitor that blocks the HER2 receptor. In China it is known as 圣赫途. The China-Mainland version is supplied as 60 mg film-coated tablets in a 60-tablet bottle, which conveniently covers a full month of treatment for many patients. Unlike older intravenous HER2-directed therapies, zongertinib is taken once daily by mouth, which makes long-term treatment substantially easier to manage at home.

How Does Zongertinib Work?

Zongertinib selectively binds to and inhibits the HER2 (also called ERBB2) tyrosine kinase domain, blocking the abnormal growth signals that drive tumours with HER2 activating mutations. Because it is designed to spare the closely related wild-type EGFR, it aims to deliver anti-tumour activity against the HER2-mutant clone while limiting some of the toxicities seen with broader EGFR inhibitors. This selectivity is a key part of why it was developed for the specific molecularly-defined NSCLC population it serves.

Indications

The China-Mainland version of Hernexeos is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumours harbour a HER2 (ERBB2) tyrosine kinase domain activating mutation, as detected by a validated test. It is used after the cancer has progressed on or after prior systemic therapy. Because the indication depends on a specific molecular marker, confirmatory HER2 mutation testing is an essential first step before treatment.

Dosage

The recommended dose of zongertinib is weight-based. Patients who weigh less than 90 kg take 120 mg once daily (two 60 mg tablets), while patients who weigh 90 kg or more take 180 mg once daily (three 60 mg tablets). A single 60 mg × 60 tablet bottle therefore provides a full 30-day supply for patients below 90 kg, and roughly 20 days for heavier patients. Treatment continues until disease progression or unacceptable toxicity, and any dose adjustment should be guided by the prescribing physician.

Side Effects

The most commonly reported side effects of zongertinib include diarrhoea, rash, stomatitis, decreased appetite, fatigue, and abnormalities in liver function tests. Some patients may also experience nausea, anaemia, or changes in certain blood counts. Most reactions are mild to moderate and can often be managed with supportive care or dose modification. Because liver and cardiac monitoring may be recommended during treatment, patients should keep all scheduled follow-up appointments and report any new or worsening symptoms to their doctor promptly.

Storage

Store Hernexeos tablets at room temperature, away from excess heat and moisture, and keep the bottle tightly closed in its original packaging. Keep the medicine out of the sight and reach of children, and do not use it after the expiry date printed on the label. As with all oral oncology medicines, keep a clear record of the batch number and source for traceability.

Why Choose the China-Mainland Version of Hernexeos?

Choosing the China-Mainland version of Hernexeos means choosing the originator molecule with the full NMPA marketing authorization, supplied in a practical 60 mg × 60 tablet bottle. The most compelling practical reason is affordability: the China-Mainland originator is priced substantially below the United States list price — by a margin of well over half — and is also noticeably more economical than the smaller Japanese pack when compared on a per-tablet basis. Patients and institutions sourcing the China-Mainland version gain genuine price relief without leaving the originator supply chain. This is a significant cost advantage over other markets, while remaining the same Boehringer Ingelheim originator product.

How to Order Zongertinib (China-Mainland)

To order the China-Mainland version of Hernexeos, contact GLT through the channels below. A valid prescription and confirmation of HER2 mutation status are required. Our team can advise on current availability, documentation, and delivery arrangements for both individual patients and institutional buyers.

WhatsApp: +86 15234153837  |  Email: [email protected]

FAQ

Is zongertinib available in China? Yes. Zongertinib (圣赫途 / Hernexeos) has received NMPA approval in China and is available through designated pharmacies. It is currently not covered by the national reimbursement drug list, so patients pay out of pocket.

How much does zongertinib cost in China? The China-Mainland originator is priced meaningfully below the United States list price and is more economical per tablet than the smaller Japanese pack. For an exact current quote, please contact our team directly.

What is the difference between Hernexeos and LuciZonger? Hernexeos is the originator brand from Boehringer Ingelheim; LuciZonger is a licensed generic version manufactured in Laos. Both contain the same active ingredient, zongertinib, and both are supplied as 60 mg × 60 tablets.

Do I need a HER2 test before taking zongertinib? Yes. Zongertinib is only indicated for NSCLC with a HER2 (ERBB2) tyrosine kinase domain activating mutation, so confirmatory molecular testing is required before starting treatment.

What strength does zongertinib come in? Zongertinib is supplied as 60 mg oral tablets, typically in a 60-tablet bottle for the China-Mainland version.

Related Oncology Products

Lumakras (Sotorasib) 120mg Tablets | KRAS G12C NSCLC & mCRC | Amgen US | GLT

Amgen's first-in-class KRAS G12C inhibitor, FDA-approved for KRAS G12C-mutated NSCLC and mCRC.

Selpercatinib (LuciSel) 40mg — RET-Driven Cancer | GLT

Generic selpercatinib (Lucius) for RET-driven lung and thyroid cancer

Osimitib (Osimertinib) 80mg*30 | Laos Alliance Generic | GLT

Laos Alliance Pharmaceutical Group — registered osimertinib 80mg generic (03 L 0953/23)

Selpercatinib (Sepadx) 40mg — RET-Driven Cancer | GLT

Generic selpercatinib (Bigbear) for RET-driven lung and thyroid cancer

Zongertinib (Hernexeos) 60mg | Germany Originator HER2 Inhibitor for NSCLC | GLT

Originator zongertinib (Hernexeos) for HER2-mutant NSCLC, 60mg × 60 tablets.

Zongertinib (LuciZonger) 60mg | Laos Generic HER2 Inhibitor for NSCLC | GLT

Registered Laos generic zongertinib for HER2-mutant NSCLC, 60mg × 60 tablets.

Lumakras (Sotorasib) 120mg Tablets | KRAS G12C NSCLC & mCRC | Amgen Boao China | GLT

Amgen's first-in-class KRAS G12C inhibitor, supplied from the Boao (Hainan) medical pilot zone — first...

Selpercatinib (Retevmo) — RET-Driven Lung & Thyroid Cancer | GLT

FDA-approved selective RET kinase inhibitor for RET fusion-positive NSCLC and thyroid cancer